Navigation Links
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of MAP Pharmaceuticals, Inc. - MAPP
Date:1/23/2013

NEW YORK, Jan. 23, 2013 /PRNewswire/ -- Pomerantz Grossman Hufford Dahlstrom & Gross LLP is investigating claims on behalf of investors of MAP Pharmaceuticals, Inc. ("MAP Pharmaceuticals" or the "Company") (NASDAQ: MAPP) (ISIN: US56509R1086) (CUSIP: 56509R108) concerning the proposed acquisition of MAP Pharmaceuticals by Allergan, Inc. in a transaction valued at approximately $985 million in cash.

The investigation concerns whether the MAP Pharmaceuticals directors are breaching their fiduciary duties by failing to adequately shop the Company and maximize shareholder value.  Under the terms of the agreement, MAP Pharmaceuticals shareholders will be entitled to receive $25.00 per share in cash for each share of MAP Pharmaceuticals common stock.  However, at least one analyst noted that the offered price undervalues MAP Pharmaceuticals' new migraine treatment drug Levadex.

MAP Pharmaceuticals shareholders seeking more information about this acquisition are advised to contact Robert Willoughby at rswilloughby@pomlaw.com or 212-661-1100 or 888-476-6529, ext. 237.

The firm is also investigating actions on behalf of shareholders for the following companies: Arbitron Inc., Net1 Ueps Technologies, Inc., Hi-Crush Partners LP, Intermec, Inc., SandRidge Energy, Inc., Abiomed, Inc., Universal Technical Institute, and Clearwire Corporation, Ameristar Casinos, Inc. K-Swiss, Inc., Neptune Technologies Bioressources, Inc. Telanetix, Inc.

The Pomerantz Firm, with offices in New York, Chicago and San Diego, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz , known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 75 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of defrauded investors. See www.pomerantzlaw.com.


'/>"/>
SOURCE Pomerantz Grossman Hufford Dahlstrom & Gross LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BD Announces Webcast of Annual Meeting of Shareholders
2. Accelr8 to Hold 2012 Annual Meeting of Shareholders; Product Development Continues with Launch Expected in 2015
3. SHAREHOLDER ALERT: Morgan & Morgan announces an investigation of Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and whether senior management and the board of directors violated fiduciary duties owed to Vertex shareholders.
4. Delaware Court of Chancery Dismisses Vermillion Dissident Shareholder Suit with Prejudice
5. SurgLine International, Inc. Shareholder Update
6. Ampio Provides Progress Report on Clinical Programs in Preparation for Annual Shareholders Meeting
7. Cannabis Science Provides Corporate Guidance on Preclinical Initiatives and Recent Corporate Developments for its Shareholders; CBIS Announces plans for 1st Q of 2013 Webinar Investor Call
8. Winner Medical Announces Mailing of Definitive Proxy Materials for Special Meeting of Shareholders
9. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2012 Annual General Meeting
10. Medbox Announces Increase in Shareholder Base and Record Revenue Generated in Q3
11. Cardinal Health Announces Preliminary Shareholder Voting Results at 2012 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ... on the development of oral drug delivery systems, announced today ... conference, presented by Joseph Gunnar & Co. LLC, ... York . Nadav Kidron , CEO of Oramed, ... Presentation Details:   PIONEERS 2016, presented by ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... April 27, 2016   ... Growth in Recurring Consumable Sales  Clinical sales ... Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, ... sales for the first quarter ended March 31, 2016 ... execution of its commercial strategy. First Quarter ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... Foundation, the national charitable foundation serving the footwear industry, has broken all previous ... more than 130 companies across 23 states during the months of April and ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Awakening , announces the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress ... Onnit brain and mood optimization products to the store is just one more ...
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, ... the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, the “Rural ... (R - Cumming), offers a 70% tax credit to individuals and corporations which donate ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... and author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related ... 2016 and podcasted thereafter . Dr. Bernie Siegel, author of a plethora ...
(Date:4/29/2016)... STAMFORD, CONNECTICUT (PRWEB) , ... April 29, 2016 , ... ... 5K Run/Walk” at Cove Island Park on Sunday, with sunny skies, a light breeze ... event, raising nearly $33,000. , The 5k Run and Walk and 1-mile ...
Breaking Medicine News(10 mins):